Rare Disease Landscape: Will the Blockbuster Model Be Replaced?

Expert Opinion on Orphan Drugs - United Kingdom
doi 10.1517/21678707.2014.924850
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare